ClinicalTrials.gg

TargetBeta

KAT6B

lysine acetyltransferase 6B · also querkopf, qkf, Morf, MOZ2 · PHD finger proteins

7 programs in company-led studies act on KAT6B, from 6 companies: 1 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
prifetrastatPfizerphase 3105 runningKAT6Athe company's pipeline
KAT6A/B Inhibitor BG-75202ruleBeOne Medicinesphase 122 runningKAT6ANCIt
HRS-2189Jiangsu HengRui Medicinephase 121 runningKAT6Athe company's pipeline
HLX97Fosun Pharmaphase 111 runningKAT6Athe company's pipeline
KAT6 Inhibitor OP-3136ruleOlema Pharmaceuticalsphase 111 runningKAT6ANCIt
KAT6/KAT7 Inhibitor IDE574ruleIDEAYA Biosciencesphase 111 runningKAT6A, KAT7NCIt
KAT6/KAT7 Inhibitor PF-08032562rulePfizerphase 111 runningKAT6A, KAT7NCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.